HomeCompareVKSC vs ABBV

VKSC vs ABBV: Dividend Comparison 2026

VKSC yields 19.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $30.9K in total portfolio value· pulled ahead in Year 9
10 years
VKSC
VKSC
● Live price
19.65%
Share price
$10.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.5K
Annual income
$6,488.77
Full VKSC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VKSC vs ABBV

📍 ABBV pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVKSCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VKSC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VKSC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VKSC
Annual income on $10K today (after 15% tax)
$1,670.01/yr
After 10yr DRIP, annual income (after tax)
$5,515.45/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $15,540.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VKSC + ABBV for your $10,000?

VKSC: 50%ABBV: 50%
100% ABBV50/50100% VKSC
Portfolio after 10yr
$86.9K
Annual income
$15,630.27/yr
Blended yield
17.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VKSC
No analyst data
Altman Z
1.0
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VKSC buys
0
ABBV buys
0
No recent congressional trades found for VKSC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVKSCABBV
Forward yield19.65%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$71.5K$102.3K
Annual income after 10y$6,488.77$24,771.77
Total dividends collected$40.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VKSC vs ABBV ($10,000, DRIP)

YearVKSC PortfolioVKSC Income/yrABBV PortfolioABBV Income/yrGap
1$12,665$1,964.72$11,550$430.00+$1.1KVKSC
2$15,877$2,325.48$13,472$627.96+$2.4KVKSC
3$19,713$2,724.55$15,906$926.08+$3.8KVKSC
4$24,254$3,161.51$19,071$1,382.55+$5.2KVKSC
5$29,587$3,635.38$23,302$2,095.81+$6.3KVKSC
6$35,803$4,144.63$29,150$3,237.93+$6.7KVKSC
7$42,996$4,687.23$37,536$5,121.41+$5.5KVKSC
8$51,267$5,260.73$50,079$8,338.38+$1.2KVKSC
9← crossover$60,718$5,862.28$69,753$14,065.80$9.0KABBV
10$71,457$6,488.77$102,337$24,771.77$30.9KABBV

VKSC vs ABBV: Complete Analysis 2026

VKSCStock

Viskase Companies, Inc., together with its subsidiaries, produces and sells nonedible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products in North America, South America, Europe, Asia, and internationally. The company offers NOJAX cellulose casings for use in the automated production of hot dogs, dry mini salamis, and cooked and coarse ground sausages; and large cellulose casings for giving cylindrical or oval shape to the processed meats that are used in bologna, mortadella, deli ham, bierwurst, and dry sausages. It also provides fibrous casings for use in a range of applications, including pepperoni, salami, luncheon meats, boneless hams, and other deli-style processed meats, as well as for processed and smoked cheeses; color transfer casings for a range of natural and synthetic shades; flavor transfer casings for taste profiles; smoke transfer casings for processed meat or cheese products; and spice transfer casings for processing facility. In addition, the company offers VISDRY casings for dried or smoked sausages; VISFLEX casings for cheese and processed meat; VISFLEX casings for a range of cheese and processed meat applications; VISMAX casings for molded, and formed processed meat and poultry applications; VISLON for meat, poultry, and cheese applications; VISMOKE casings for cooked and smoked meat products, semi-dry sausages, and spreadable dry sausages; VISCOAT casings for a range of applications, including turkey, ham, and roast beef products; and POLYJAX casings for the production of hot dog, sausage, chorizo products, and meat snack sticks. Further, it offers textile spice transfer casings for transfer of the spice to the food and MEMBRA-CEL, a dialysis membrane made from regenerated cellulose. The company was founded in 1925 and is based in Lombard, Illinois. Viskase Companies, Inc. is a subsidiary of Icahn Enterprises L.P.

Full VKSC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VKSC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VKSC vs SCHDVKSC vs JEPIVKSC vs OVKSC vs KOVKSC vs MAINVKSC vs JNJVKSC vs MRKVKSC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.